Figure 3.

Sifalimumab inhibition of overexpression of the type I interferon signature in systemic lupus erythematosus patients. Dose responses of sifalimumab therapy in whole blood of systemic lupus erythematosus (SLE) patients with an overexpressed type I interferon-inducible gene signature as measured by the type I interferon-inducible gene signature score. Neutralization of the 21 type I interferon-inducible mRNAs by treatment averaged for each dose cohort observed from day 0 (pretreatment) to day 7 (posttreatment). y axis, values calculated as the fraction of neutralization of certain days post-treatment/pretreatment (day 0 predosing), subtracted from 1 for each patient separately. Those values that exceed 1 from this formula are a result of an increase in transcript levels of type I interferon-inducible mRNAs in whole blood following treatment (mostly in placebo-treated SLE patients). Significance for the difference between dose levels and placebo treatment using Hotelling's T2 test: 0.3 mg/kg, P = 0.09; 1 mg/kg, P = 0.04; 3 mg/kg, P = 0.01; 10 mg/kg, P = 0.007; 30 mg/kg, P = 0.004. From top to bottom: red line, placebo; blue line, 0.3 mg/kg sifalimumab; green line, 1 mg/kg sifalimumab; orange line, 3 mg/kg sifalimumab; black line, 10 mg/kg sifalimumab; pink line, 30 mg/kg sifalimumab.

Yao et al. Arthritis Research & Therapy 2010 12(Suppl 1):S6   doi:10.1186/ar2887